Article

Combined Metabolic Activators decrease liver steatosis by activating mitochondrial metabolism in a Golden Syrian hamster study

2021-02-19

Abstract excerpt

The prevalence of non-alcohol fatty liver disease (NAFLD), defined as the liver’s excessive fat accumulation, continues to increase dramatically. We have recently revealed the molecular mechanism underlying NAFLD using in-depth multi-omics profiling and identified that combined metabolic activators (CMA) could be administered to decrease the amount of hepatic steatosis (HS) in mouse model and NAFLD patients based...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fd54d83e-07e3-53e8-bf9c-6c9cb2d8cd3e
DOI: 10.1101/2021.02.19.431968

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Combined Metabolic Activators decrease liver steatosis by activating mitochondrial metabolism in a Golden Syrian hamster studyDOI 10.1101/2021.02.19.431968Read

A novel, multitargeted endogenous metabolic modulator composition impacts metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis-relevant primary human cell models.Semantic proximity Read

ACACA reduces lipid accumulation through dual regulation of lipid metabolism and mitochondrial function via AMPK- PPARα- CPT1A axisSemantic proximity Read

Integration of Multi-omics Data from Mouse Diversity Panel Highlights Mitochondrial Dysfunction in Non-alcoholic Fatty Liver Disease.Semantic proximity Read

Metabolomics and Lipidomics Screening Reveal Reprogrammed Signaling Pathways toward Cancer Development in Non-Alcoholic SteatohepatitisSemantic proximity Read

Thyroid Hormone and Mitochondrial Dysfunction: Therapeutic Implications for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Semantic proximity Read

Shenling Baizhu San Ameliorates Metabolic-Associated Fatty Liver Disease Complicated with Sarcopenia via Regulating AMPKα SignalingSemantic proximity Read

The Effect of Cardiometabolic Drugs on Non-Alcoholic Fatty Liver Disease (NAFLD), Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Semantic proximity Read

Phenotyping the effect of diet on non-alcoholic fatty liver disease.Semantic proximity Read

Corydalis Saxicola Bunting Total Alkaloids alleviate nonalcoholic fatty liver disease via regulating mitochondrial homeostasisSemantic proximity Read

PPARα-ERRα crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progressionSemantic proximity Read

Transcriptome and translatome analyses reveal the regulatory role of betaine in high fat diet (HFD)-induced hepatic steatosisSemantic proximity Read

A new dietary rat model fully recapitulates metabolic dysfunction-associated steatotic liver disease pathophysiology and mimics human disease with advanced liver fibrosis and portal hypertensionSemantic proximity Read